Docetaxel versus epirubicin/cyclophosphamide(EC) as first-line therapy in metastatic breast cancer (MBC): results from the randomized phase II TIPP study

被引：0
|
作者：
不详
机构：
来源：
BREAST | 2005年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [1] Docetaxel versus epirubicin/cyclophosphamide (EC) as first-line therapy in metastatic breast cancer (MBC): Results from the randomized phase II TIPP study.
    Wasemann, C
    Ertan, A
    Strunck, C
    Schmidt, W
    Diedrich, K
    Friedrich, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 82S - 82S
  • [2] Randomized phase II study of docetaxel vs. epirubicin/cyclophosphamide to optimize first-line therapy of metastatic breast cancer (MBC): preliminary results of the TIPP study.
    Wasemann, C
    Di Liberto, A
    Ertan, K
    Schmidt, W
    Friedrich, M
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S89 - S89
  • [3] Docetaxel with epirubicin as first line chemotherapy in metastatic breast cancer (MBC).: Final results of a Phase II study
    Morales, S
    Lorenzo, A
    Ramos, M
    Ballesteros, P
    Méndez, M
    Almanza, C
    Moreno-Nogueira, J
    Casal, J
    Castellanos, J
    Lizón, J
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S68 - S68
  • [4] Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial
    Blohmer, J. -U.
    Schmid, P.
    Hilfrich, J.
    Friese, K.
    Kleine-Tebbe, A.
    Koelbl, H.
    Sommer, H.
    Morack, G.
    Wischnewsky, M. B.
    Lichtenegger, W.
    Kuemmel, S.
    ANNALS OF ONCOLOGY, 2010, 21 (07) : 1430 - 1435
  • [5] Safety and efficacy of first-line epirubicin-docetaxel (ED) versus epirubicin-cyclophosphamide (EC): A multicenter randomized phase III trial in metastatic breast cancer
    Blohmer, JU
    Hauschild, M
    Hilfrich, J
    Kleine-Tebbe, A
    Kuemmel, S
    Lichtenegger, W
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 34S - 34S
  • [6] Multicenter randomized phase III study evaluating epirubicin/cyclophosphamide (EC) versus epirubicin/docetaxel (ED) for first line treatment of metastatic breast cancer (MBC): an interim analysis of safety and efficacy.
    Blohmer, JU
    Lichtenegger, W
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S90 - S90
  • [7] A phase I/II study of docetaxel/epirubicin/bevacizumab (DEB) as first-line therapy for metastatic, HER2-negative breast cancer (MBC).
    Mavroudis, D.
    Boukovinas, I.
    Christophyllakis, C.
    Xenidis, N.
    Papakotoulas, P.
    Malamos, N. A.
    Kakolyris, S.
    Polyzos, A.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Safety and efficacy of first-line epirubicin-docetaxel versus epirubicin-cyclophosphamide: updated results of a multicenter randomized phase III trial in metastatic breast cancer.
    Blohmer, JU
    Houschild, M
    Hilfrich, J
    Kleine-Tebbe, A
    Lichtenegger, W
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S199 - S199
  • [9] Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer
    Nabholtz, JM
    Mackey, JR
    Smylie, M
    Paterson, A
    Noël, DR
    Al-Tweigeri, T
    Tonkin, K
    North, S
    Azli, N
    Riva, A
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) : 314 - 321
  • [10] First-line chemotherapy of advanced or metastatic breast cancer (MBC) with docetaxel and doxorubicin in Indonesia: results from A phase II trial
    Abdulmuthalib
    Darwis, Idral
    Prayogo, Nugroho
    Sutjipto
    MEDICAL JOURNAL OF INDONESIA, 2005, 14 (01) : 20 - 25
12345